High Content & Phenotypic Screening 2017 Agenda

Registration

Re-building & Imaging the Complexity and Heterogeneity of Human Cancer Tissues for Phenotypic Screening in 3D Models
Matthias Nees, Group Leader, University of Turku, Finland

Engineered Tissue in Phenotypic Drug Screens
Wolfram-Hubertus Zimmermann, Professor, University Medical Center Goettingen, Germany

Coffee & Networking in Exhibition Hall

Developing Complex Cellular Models to Increase Phenotype and Disease Relevance in Drug Discovery
Christopher Schofield, Group Leader/Investigator, GlaxoSmithKline, United Kingdom

This talk will describe how we are using 3D spheroids and microtissue methods to investigate hepatotoxicity. How they compare to current 2D models and how we can move forward to improved screening of compounds.

Phenotypic Drug Profiling in Human Primary Cell Systems to Better Understand, Compare and Optimize Drugs
Alexander Baumann, Senior Director, DiscoveRx Corporation, United Kingdom

DiscoverX has developed a phenotypic profiling platform that is based on Human Primary Cell Disease Models. We present how these models can be applied for the analysis of MoA of drugs and optimization of lead compounds.

Technology Spotlight:
High Content Death in the Far-red
Roy Edward, Director, Biostatus Ltd

The far-red viability probe DRAQ7(TM) uniquely enables a) cell health monitoring in dynamic real-time, time-lapse cell-based assays and b) channel-free dead cell exclusion in flow cytometry/cell sorting.

Lunch & Networking in Exhibition Hall

Poster Viewing Session

3D Imaging and 2D Quantification of Mitochondrial Potential of Confocal Slices in Tumor Spheroids Acquired by Using High Content Analysis, Quantitative Fluorescence Microscopy
Andrew Barlow, Field Application Specialist, Thermo Fisher Scientific, United Kingdom

This short presentation will focus on the analysis of 2 different head and neck tumor cell lines, Cal33 and FaDu, using the Thermo Scientific CellInsight™ CX7 to measure spheroid morphology and cell level mitochondrial potential using TMRM.

Development of Phenotypic High-Content Assays for Compound Screening and Hit Validation
Kamyar Hadian, Group Leader, Helmholtz Zentrum München, Germany

High-Content Screening (HCS) assays for primary screening and secondary hit validation offer a powerful tool to analyze more biologically relevant systems. We have developed high-content assays for compound screening in various areas including stem cells and 3D cell culture.

Technology Spotlight:
siPOOLs – Application in High Content Screening and Target Validation
Catherine Goh, Head of Product Development and Marketing, siTOOLs Biotech GmbH

siPOOLs are complex pools of 30 carefully selected siRNAs which silences genes with far greater specificity and robustness than current RNAi reagents. Learn about the technology and its application in high content screening.

Coffee & Networking in Exhibition Hall

High Throughput Microscopy Toxicity Pathway Reporters for Drug Safety Assessment
Bob Van de Water, Professor, Leiden University, Netherlands

A high content imaging-based cellular stress response fluorescent protein reporter platform will be discussed. This liver cell-based platform is suitable for phenotypic screening in 2D and 3D spheroids to quantify and qualify the activation of stress pathway for both drug discovery and safety assessment.

Cellular Basis of Toxicity and Specific Toxicity Testing by High Content Imaging
Armin Wolf, Professor/Director, Novartis Institutes for BioMedical Research, Switzerland

Drinks Reception in Exhibition Hall

End of Day 1

High Content and Phenotypic Screening User Group Meeting
Please register using this link

HipSci Cell Phenotyping: Building High Content Analysis Platforms to Characterise Human Induced Pluripotent Stem Cell Lines
Davide Danovi, Director, Cell Phenotyping Platform, Kings College London, United Kingdom

The human induced pluripotent stem cells initiative, a resource for the scientific community • Characterisation of large panels of stem cells using high content image analysis.  Collaborative phenotype screening strategies for academia and industry.

Modeling Human CNS Disease with Patient Derived Cells : Combining the Power of Stem Cells and Phenotypic Screening in Drug Discovery
Michael Jackson, Senior Vice President, Drug Discovery and Development, Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, United States of America

This talk will focus on our progress in combining the power of human induced pluripotent stem cell (iPSC)-derived neurons, phenotypic screens and live cell functional assays to both model disorders of the nervous system and search for drugs to treat disease them.

Technology Spotlight:
How to Assess Phenotypic Changes with High Speed and Accuracy
Matthias Fassler, Scientific Account Manager, Genedata

Phenotypic high content screens frequently rely on complex cell-based disease models to investigate different pathologies. Here we show how Genedata Screener facilitates the QC of such screens and thereby allows to leverage their full potential.

Coffee & Networking in Exhibition Hall

Catalyzing Translation through Improved Processes of Disease and Toxicity Screening
Anton Simeonov, Scientific Director, National Institutes of Health, United States of America

The presentation will provide an overview of novel approaches in disease model-building through collaborative stem cell and 3D tissue bioprinting technology development, construction of screening libraries of approved and investigational agents, and the processes of early-stage drug repurposing.

Technology Spotlight:
High Content Screening for Quantitative Biology
Jacob Tesdorpf, Director, Perkin Elmer

With the latest generation of modern high content analysis systems and advances both in hardware and software available, we will show solutions to the challenges of interrogating more physiologically relevant and complex cell models systems, such as co-cultures, 3D cell models, and tissues.

Lunch & Networking in Exhibition Hall

Poster Viewing Session

High Content Screening of Nanopeptides used for siRNA delivery
Stephen Brown, RNAi Facility Screening Manager, Sheffield University, United Kingdom

Coffee & Networking in Exhibition Hall

Using Image-omics to Understand the Relationship between Cell Shape and Transcription in Cancer Cells
Chris Bakal, Dynamical Cell Systems Team Leader, Institute of Cancer Research, United Kingdom

I will discuss how we can leverage the rich datasets generated by high-content approaches using integrative “image-omics” to gain insight into the wiring and dynamics of signal transduction networks, and thus open up new therapeutic avenues.

Improving Reproducibility in Cell based Experiments
Anthony Davies, Director of Translational Cell Imaging, The Queensland University of Technology, Australia

Over the last few years there have been a number of reports highlighting the problem of poor reproducibility in biological research, this presentation will describe our plans and current progress in attempting to address the issue specifically in the area of cell based assays and phenotypic screening.

Close of Conference